RxDoctor Payments Data

Mehul Raval, MD

Nephrology · Stockton, CANPI 1710157474

Payments from drug & device makers

$966in general payments, 2019–2025

Across 35 payments — averaging $27.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$270
  • Fresenius USA Marketing, Inc.$180
  • AstraZeneca$128
  • Bard Peripheral Vascular, Inc.$95
  • Amgen$73
  • Akebia Therapeutics Inc$46
  • plus $174 from 8 others

What the payments were for

  • Speaking & faculty fees$20021%
  • Food & beverage$74477%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$966 in reported general payments places this provider in the 45th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$265,809
Medicare patients
286
Services billed
1,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl19$65,410
VelphoroSucroferric Oxyhydroxide11$29,469
AuryxiaFerric Citrate11$29,258
EliquisApixaban12$11,027
Sevelamer Carbonate40$6,672
Calcium Acetate42$4,126
ProsolParenteral Amino Acid 20% No.147$2,013
Tacrolimus13$1,735
Nifedipine ErNifedipine20$966
Tamsulosin Hcl13$302
Furosemide22$196
Hydralazine Hcl14$184
Amlodipine Besylate28$177
Carvedilol14$110
Atorvastatin Calcium11$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$180$29,46911 claims
Akebia Therapeutics IncAuryxia$46$29,25811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,341 nephrology providers in California.

Other nephrology in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →